Introduction
Worldwide at least 2.8 million people die each year as a result of being overweight or obese. 1, 2 Among the constellation of weightrelated co-morbidities, cardiovascular disease (CVD) carries the largest burden for obese patients. 3, 4 Indeed, the risk of coronary heart disease and ischaemic stroke rises steadily with increasing body mass index. 5 A large body of evidence supports the notion that endothelial dysfunction contributes to the pathogenesis of obesity-related CVD. 6 Seminal work has revealed that generation of reactive oxygen species (ROS) is a key event preceding the development of endothelial dysfunction and vascular atherosclerotic disease in this setting. 6, 7 Furthermore, the expression of several pro-oxidant genes is derailed in obese subjects and may participate to adverse vascular phenotypes. 8, 9 However, the molecular orchestrators of vascular redox signalling remain to be fully elucidated. Plastic modifications of chromatin architecture have shown to repress or activate gene expression, thus representing a novel underpinning of disease states. [10] [11] [12] Eukaryotic chromatin is structured into highly organized complexes-nucleosomes-which include chromosomal DNA packaged around histone proteins. 13 A key mode of regulation that controls chromatin organization is the covalent modification (i.e. acetylation and methylation) of specific aminoresidues on histone tails. 10 These modifications may cluster in different patterns to regulate chromatin accessibility. 14 For example, acetylation of histone 3 at lysine 9 (H3K9ac) residue is associated with an open chromatin and active gene transcription, whereas H3K9 methylation favours the shift towards heterochromatin, characterized by condensed and repressed genomic regions. 15 Understanding the regulation of ROS-generating pathways is one of the most important challenges in cardiovascular research. 16 Reactive oxygen species, besides irreversibly modifying organelles and macromolecules, also trigger important events such as senescence, inflammation, and multiple cell death pathways. 16 In this regard, the adaptor p66 Shc protein is part of a complex mitochondrial system regulating endogenous production of free radicals and apoptosis. 17, 18 In the mitochondrial intermembrane space, p66 Shc oxidizes cytochrome c shifting electrons towards the production of ROS and subsequent opening of permeability transition pore (PTP). 19, 20 This latter event increases mitochondrial membrane permeability to ions, solutes, and water triggering swelling and disruption of the organelle with release of proapoptotic factors. 21 ShcÀ/À mouse models exposed to high oxidative stress. 17, 23 Moreover, reduced production of ROS resulting from inhibition of p66 Shc pathway is associated with preservation of mitochondrial integrity and resistance to apoptosis induced by a variety of different mediators such as hydrogen peroxide, growth factor deprivation, and ultraviolet radiation. 6, 19 In this study, we show that a complex interplay among chromatin remodellers SUV39H1, JMJD2C, and SRC-1 drives the transcription of the adaptor p66 Shc and subsequent endothelial dysfunction in the vasculature of obese subjects and mice. These mechanistic insights offer novel molecular targets pointing towards potential epigenetic drugs for the prevention of oxidative burst and vascular dysfunction in obesity.
Methods
A detailed description of the Methods is reported in Supplementary Material online.
Study population
Obese patients were recruited among 220 consecutive patients from January 2010 to January 2014 for screening in view of laparoscopic bariatric surgery. Control subjects were recruited among patients hospitalized in the Surgery Unit (University of Pisa, Italy) to undergo laparoscopic surgery for cholecystectomy. The study protocol was approved by local ethics committee, and, in accordance with institutional guidelines, all participants were aware of the investigational nature of the study and signed a written consent for their participation.
Preparation of small visceral fat arteries
Small visceral fat arteries (150-300 mm, approximately 2 mm long) were isolated from visceral fat immediately after biopsy sample procurement, performed during laparoscopic surgery, and mounted on 2-glass microcannulae in a pressurized myograph, as previously described. 
Statistical analysis

Results p66 Shc up-regulation and endothelial dysfunction in obese subjects
We first investigated the link between p66
Shc gene expression, oxidative stress, and endothelial dysfunction in visceral fat arteries (VFAs) isolated from 21 obese and 20 control subjects. Characteristics of study population are shown in Table 1 . Isometric tension studies in VFA showed an impairment of acetylcholine-induced vasorelaxation in obese subjects when compared with the controls ( Figure 1A ), whereas response to sodium nitroprusside (SNP) did not differ between the two groups (see Supplementary material online, Figure  S1 ). Pretreatment with the antioxidant ascorbic acid restored relaxation to acetylcholine, suggesting that ROS contribute to endothelial dysfunction in this setting ( Figure 1A ). Gene expression of p66 Shc was significantly higher in obese when compared with the control VFA ( Figure 1B) . Moreover, messenger RNA levels of p66 Shc negatively correlated with endothelium-dependent vasorelaxation in VFA from obese patients ( Figure 1C ).
Obesity-induced epigenetic remodelling of p66 Shc promoter
To investigate epigenetic regulation of p66 Shc in obesity, real-time PCR array for chromatin-modifying enzymes was performed in VFA isolated from obese and normal weight individuals. A dysregulation of 27 of 84 total genes was observed in obese when compared with control VFA. Of these, 21 were up-regulated and 6 down-regulated by more than two-fold ( Figure 2A , see Supplementary material online, Table S1 ). Since epigenetic regulation of p66 Shc occurs on histone 3
(H3)-binding human promoter region, chromatin immunoprecipitation (ChIP) was performed to unveil the H3 epigenetic modifiers interacting with p66 Shc promoter ( Figure 2B ). ChiP assays showed that only methyltransferase SUV39H1, demethylase JMJD2C, and Figure S2 ). Di-(H3K9me2) and tri-methylation (H3K9me3) of H3K9 on p66 Shc promoter were reduced, whereas H3K9 acetylation (H3K9ac) was increased in obese when compared with the control VFA ( Figure 2D ). showed similarly increased body weight and dysglycaemia when compared with WT littermates (see Supplementary material online, Figure S3 ). In line with human findings, p66 Shc gene expression was significantly higher in the vasculature of obese mice ( Figure 3A) . Endothelium-dependent relaxation to acetylcholine was impaired in Lep Ob/Ob when compared with WT littermates, whereas doublemutant mice were protected against endothelial dysfunction ( Figure  3B ). In contrast, relaxation to SNP did not change across the different groups (see Supplementary material online, Figure S4 ). The O -2 scavenger polyethylene glycol-superoxide dismutase (PEG-SOD) rescued the response to acetylcholine in obese Lep Ob/Ob mice, thus confirming that endothelial dysfunction is driven by ROS ( Figure 3C ).
Reprogramming H3K9-editing enzymes suppresses obesity-induced p66 Shc transcription and endothelial dysfunction Methyltransferase SUV39H1 triggers p66 Shc expression by orchestrating chromatin accessibility Although SUV39H1, JMJD2C, and SRC-1 are all critically involved in epigenetic regulation of p66 Shc , it was crucial to unmask a putative molecular hierarchy among them. By ChIP experiments, we found that recruitment of acetyltransferase SRC-1 to p66
Shc promoter is significantly reduced in the vasculature of obese mice treated with either SUV39H1 overexpressing vector or JMJD2C siRNA ( Figure  4C ). In contrast, knockdown of SRC-1 did not affect the interaction of SUV39H1 and JMJD2C with p66 Shc promoter. Interestingly, only SUV39H1 overexpression hampered the recruitment of both JMJD2C and SRC-1 leading to repression of p66 Shc transcription ( Figure 4C ). Our findings are strengthened by the observation of p66 Shc up-regulation in the aorta of lean SUV39H1 À/À mice ( Figure   4D ). Accordingly, we found that genetic deletion of SUV39H1 
Discussion
In this study, we demonstrate in a translational approach that reversible epigenetic signatures drive up-regulation of the mitochondrial adaptor p66 Current knowledge of the molecular pathways underlying vascular disease in patients with obesity is limited. The interaction between gene and environment as a putative mechanism for obesity-related vascular complications remains poorly understood. [25] [26] [27] Previous work has shown that epigenetic editing of H3K9 is associated with deregulation of metabolic genes, appetite changes, insulin signalling defects, and altered expression profile of inflammatory genes. Most importantly, H3K9-related marks significantly contribute to intergenerational metabolic reprogramming with a potentially important impact on phenotypic variation and evolution. 33 Whether variations of H3K9 landscape are associated with obesity-related oxidative signals and vascular phenotypes remains largely unknown.
28-32
Here, we showed that human and experimental obesity are associated with a specific remodelling of H3K9, characterized by reduced H3K9me2 and H3K9me3 as well as increased H3K9ac. The observed changes on H3K9 arise from deregulation of the chromatin modifiers SUV39H1, JMJD2C, and SRC-1 interacting with p66 Shc promoter in obese VFA. As assessed by gene profiling, SUV39H1 was down-regulated, whereas JMJD2C and SRC-1 were increased. These 16 Accordingly, antioxidants only partially scavenge cellular ROS without any impact on mitochondrial redox signalling. 34 In contrast, modulation of SUV39H1 expression may represent a valid therapeutic approach to revert adverse H3K9-epigenetic remodelling and p66
Shc -driven vascular oxidative stress in obesity. Growing understanding of chromatin architecture and metabolism has led to the design of specific molecules capable of modulating chromatin accessibility via enhancement/ repression of epigenetic marks on DNA/histone complexes. 35 Noteworthy, some of these drugs have been already approved for the treatment of several conditions including cancer, neurological, and cardiovascular disease. 36 Although pharmacological activators of SUV39H1
are not yet available, ongoing high-throughput screenings of chemical libraries will be instrumental to identify selective compounds to be tested in experimental studies. 37 This study has some limitations. Although we have successfully translated our experimental findings to the human setting, we could not fully prove a causal relation between p66
Shc and endothelial dysfunction in obese patients. In this regard, pharmacological modulation of p66 Shc would have been the best approach-however, p66 
